Document:

<PAGE>

                               DATED June 25, 2002

                               LION BIOSCIENCE AG

                                       and

                            BAYER AKTIENGESELLSCHAFT

                    ----------------------------------------

                                 3/rd/ AMENDMENT

                   relating to a development agreement between
                               LION bioscience AG
                                       and
                        Bayer AG dated 13th October, 2000

                    ----------------------------------------

<PAGE>

                                       2

                                    CONTENTS
<TABLE>
<CAPTION>
Clause                                                                     Page
<S>                                                                        <C>
1.  Interpretation........................................................   4
2.  Milestone 2 A and ACCEPTANCE TEST.....................................   4
3.  Miscellaneous.........................................................   5
</TABLE>

<PAGE>

                                       3

THIS AGREEMENT is made as of June 14th, 2002 BETWEEN:

(1) LION bioscience AG ("LION"), Waldhofer Str. 98, 69123 Heidelberg, Germany,
registered with the commercial register of the local court in Heidelberg under
HR B 5706; and

(2) Bayer Aktiengesellschaft ("Bayer"), 51368 Leverkusen, Germany.

WHEREAS:

(A) On 13/th/ October, 2000, LION and Bayer entered into a novel and innovative
collaboration (the "Development Agreement") to implement existing IT tools at
Bayer but also to develop novel IT tools, such as pharmacophore informatics
tools, to significantly enhance lead identification and optimization
capabilities for pharmaceutical and agrochemical discovery and development.

(B) LION and Bayer agreed on key modifications to the Development Agreement to
be implemented in the first calendar quarter of 2002, which relate in particular
to the future milestones and payment schedule, in a 1st Amendment to the
Development Agreement dated 1/st/ December, 2001 and signed by LION on 11/th/
December, 2001.

(C) LION and Bayer agreed on modifications of the Development Agreement to be
implemented in the second calendar quarter of 2002, which relate in particular
to the future milestones and payment schedule, in a 2nd Amendment to the
Development Agreement dated March 29/th/, 2002.

(D) On June 14/th/, 2002, the parties agreed that the DELIVERABLES of the new
Milestone 2 A as defined in Annex B/II of the 2/nd/ Amendment to the Development
Agreement did not meet the criteria of the ACCEPTANCE TEST according to Annex
E/II of that Amendment.

(E) The parties agree that LION would not be able to fix the errors in the key
DELIVERABLES identified by the parties in accordance with (S) 3 (3) of the 2/nd/
Amendment to the Development Agreement, allowing Bayer to terminate the
Agreement pursuant to (S) 15 of the Development Agreement.

(F) However, the parties have agreed to allow LION another opportunity to meet
the criteria of the ACCEPTANCE TEST for Milestone 2 A. The corresponding Project
Plan (the "Project Plan") to meet these criteria was submitted to Bayer by LION
on June 19, 2002, agreed to by Bayer and thereby binding to both parties.

(G) LION and Bayer hereby wish amend the Development Agreement further as
follows.

<PAGE>

                                       4

NOW IT IS HEREBY AGREED as follows:

1. INTERPRETATION

(1)In this Agreement, including the recitals therein, all terms shall have the
same meaning as in the Development Agreement as amended by the 1/st/ Amendment
and the 2/nd/ Amendment, unless otherwise defined in this agreement or unless
the context requires otherwise.

(2) "Milestone" has the meaning given to it in clause 1(8) of the

Development Agreement.

2. Milestone 2 A and ACCEPTANCE TEST

(1) Pursuant to the Project Plan, Bayer will receive five correction releases of
the DELIVERABLES of which the fourth version will be subjected to a formal,
determinative ACCEPTANCE TEST as defined in Annex E II of the 2/nd/ Amendment.
Each correction release is due at the beginning of each month starting July 1,
2002, with the final correction release to be November 4, 2002. The parties
agree that the Project Plan, may be updated, modified and amended by mutual
agreement of the parties. These updates, modifications and amendments will be
agreed upon at the corresponding OpCom meetings and will be documented in
writing in the corresponding OpCom meetings.

The parties agree that notwithstanding the provisions of (S) 15 of the
Development Agreement, Bayer may terminate the Development Agreement with
immediate effect as soon as Bayer concludes, in its own discretion, that the
quality of one of the correction releases - with the exception of the July
release - gives rise to the reasonable expectation that LION will not be able to
meet the criteria for the new milestone 2A in the new formal ACCEPTANCE TEST
pursuant to (S) 2.(1), provided however that (a) Bayer gives LION one (1) week
written notice prior to any such termination and (b) gives LION's Chief
Executive Officer, or other designated official, the opportunity to meet on
short notice with Bayer's representatives of the Steering Committee in person
prior to any such termination for the purpose of discussing the intended
termination by Bayer at which meeting Bayer's representatives shall present and
document the basis for their expectation that LION will not be able to meet the
criteria for the new milestone 2A in the new formal ACCEPTANCE TEST.

For the avoidance of doubt, the parties confirm that subpayment 4 as defined in
     (S)2 (2) of the 2/nd/ Amendment to the Development Agreement shall not be
     due until the DELIVERABLES of milestone 2 A have been, or are deemed to
     have been, accepted by Bayer according to the procedure set forth above

In anticipation of a successful formal ACCEPTANCE TEST for milestone 2A
     according to 2 (1), the parties agree, notwithstanding (S)3 (7) of the
     2/nd/ Amendment, to extend the term of the Development Agreement - until
     July 1, 2004 without additional payments over and above the provisions of
     the

<PAGE>

                                       5

         Development Agreement as amended while their due dates will be
         postponed by six (6) months in accordance with the new term as revised
         hereby.

         Without changing the scope of the Project and without materially
         increasing the size of LION's efforts as set forth in the Development
         Agreement, the contents of future milestones (MS2b, MS3,and MS4) may be
         modified by mutual agreement of the parties to address the specific new
         needs of the following new organizations of Bayer: Bayer Health Care
         and Bayer Crop Science.

3.       MISCELLANEOUS

(1)      The Development Agreement and all of its provisions (as modified by the
         1/st/ Amendment and 2/nd/ Amendment) will continue in full force and
         effect as legal, valid and binding obligations of each of the parties
         subject to and as provided in this 3/rd/ Amendment or necessitated by
         the implementation of this 3/rd/ Amendment.

(2)      Clause 18 of the Development Agreement shall apply to this 2/nd/
         Amendment mutatis mutandis.

Executed by and on behalf of LION bioscience AG

Heidelberg, _______________________

  /s/ Friedrich von Bohlen und Halbach       /s/ Reinhard Schneider
--------------------------------------     ------------------------
Dr. Friedrich von Bohlen und Halbach       Dr. Reinhard Schneider
CEO                                        CIO

Executed by and on behalf of Bayer AG

Leverkusen, _______________________

  /s/ Jan - Anders Karlsson                  /s/ W. van den Kerckhoff
---------------------------                --------------------------
Head of Pharma Research                    Dr. W. van den Kerckhoff
Dr. Jan - Anders Karlsson                  Patents and Licensing<PAGE>

           Amendment to the Basic Agreement of June 17/th//18/th/ 1999

                                     between

                               LION bioscience AG
                                Waldhoferstr. 98,
                            69123 Heidelberg, Germany
                        represented by its managing board
                           -called "LION" hereinafter-

                                       and

                                    Bayer AG
                                51368 Leverkusen
                          -called "BAYER" hereinafter-

<PAGE>

                                      -2/2-

Due to the good experiences made in the past BAYER and LION agree to change and
amend the Basic Agreement of June 17/th//18/th/ 1999 to the following effect:

Sec. 3.7 (vi) 5/th/ sentence pertaining to the tie-breaking vote of the Chairman
of the Steering Committee shall from October 1/st/ 2000 on no longer apply.

IN WITNESS THEREOF, the parties hereto, intending to be bound hereby, have
signed this Amendment as of the dates indicated here:

Executed by and on behalf of LION bioscience AG

Heidelberg, ___________________________

/s/ Friedrich von Bohlen und Halbach       /s/ Klaus Sprockamp
---------------------------------------    -------------------------------------
Dr. Friedrich von Bohlen und Halbach       Dipl. -Wirtsch.Ing. Klaus Sprockamp
CEO                                        CFO

Executed by and on behalf of Bayer AG
Leverkusen, _____________________________

/s/ Wolfgang Hartwig                      /s/ Armin Buchmeier
---------------------------------------   --------------------------------------
Prof. Dr. Wolfgang Hartwig                Dr. Armin Buchmeier
Forschungsleitung GB PH                   Leitung KB Recht RE1<PAGE>

                                                                    Exhibit 4.10

                                 AMENDMENT NO. 2

                                     to the

                                 BASIC AGREEMENT

                           of June 17/th//18/th/ 1999

                                     between

                          BAYER AG, Leverkusen, Germany

                                       and

                     LION bioscience AG, Heidelberg, Germany

                                       and

          LION bioscience Research Inc., Cambridge, Massachusetts, USA

This second amendment (the "Second Amendment") to the Basic Agreement, dated
June 17/th//June 18/th/, 1999, (the "Agreement") as amended by Amendment No. 1
dated as of February 15, 2002, (the "First Amendment") by and between BAYER AG,
a German stock corporation with offices in Leverkusen, Germany, ("BAYER") and
LION bioscience Aktiengesellschaft, a German stock corporation with offices in
Heidelberg, Germany, ("LION") and LION bioscience Research Inc., a Delaware
corporation with offices in Cambridge, Massachusetts, United States, (the
"Company" or "LBRI") is dated as of June 27, 2003 (the "Effective Second
Amendment Date").

WHEREAS, in June 1999, BAYER and LION entered into a novel and innovative
relationship governed by the Agreement and related agreements, which was
intended to use LION's expertise in the area of life science informatics and "in
silico" drug discovery to accelerate BAYER's drug discovery activities and
processes;

WHEREAS, pursuant to the Agreement, LION was to, inter alia, deliver 500 novel
drug targets to BAYER over the five-year term of the Agreement as well as
develop certain specified IT solutions to improve the efficiency of the drug
discovery process during this time period within BAYER;

WHEREAS LION offers BAYER all LION software during the term of the Agreement by
presenting such software to BAYER's professionals;

WHEREAS for the purposes of this collaboration LION bioscience Research Inc., a
special purpose subsidiary has been incorporated;

WHEREAS the collaboration was and still is very successful BAYER generated to
LION a success-payment on the basis of the first Amendment (effective on
February 15, 2003);

WHEREAS LION offered to BAYER - as proof of its commitment - to do its best
efforts, e.g. by

                                      -1-

<PAGE>

providing additional resources in this project and/or implementing an
incentive-program, to deliver BAYER 300 additional class-B-targets until June
30, 2004 in addition to the targets as agreed upon in the Basic Agreement dd.
17/18/th/ of June 1999 under today's circumstances in order to underline its
constant commitment to the success of the collaboration;

WHEREAS such collaboration is in a certain way a 'living entity' which has to
take into account the actual situation, developments and changing needs of
either party, which led to the following understandings and clarifications on
the wording of the Agreement;

ACCORDINGLY the representatives of BAYER and LION meet - even on an executive
level - from time to time in order to discuss recent developments and their
impact on the collaboration;

ACCORDINGLY LION communicated to BAYER a Letter of Understanding in regard to
the LION's BioScout software which BAYER had already licensed before the
Agreement came into force, according to which no further license fee for
BioScout shall be due after coming into force of the Agreement;

ACCORDINGLY, as the collaboration is financed by BAYER in the way that BAYER
covers all related costs, LION pro-actively solved the only remaining open issue
in regard to certain hardware upgrades and costs for purchasing Silico Genetics'
software GeNet by guaranteeing to refund to BAYER the amounts which have already
been paid bay BAYER to LION in this regard;

WHEREAS BAYER and LION are considering appropriately BAYER's previous
investments in the LBRI-Project especially in regard to any future mutual
business-relationship in order to preserve the value of such investments;

NOW, IN ORDER TO accommodate BAYER's today's interests and needs - even before
the terms and conditions for such future collaboration are defined -, LION and
BAYER hereby agree to change the Agreement exclusively in regard to the
following:

1.       Bioinformatics Development Plan

The Parties agree that the software development defined in the Agreement will be
newly structured and performed according to Annex 1 to this Amendment.

2.       Target Validation Plan

The Parties agree to modify the Target Deliverables, respectively the Delivery
Plan as defined in the Agreement by establishing activities according to Annex 2
to this Amendment.

3.       Pricing

For the avoidance of doubt the Parties agree that the modifications mentioned in
section 1 and 2 above including the corresponding Annexes do not change in any
way the payment-structure mentioned in the Agreement; i.e. all mentioned
modifications do not cause additional costs for BAYER. Furthermore, taking into
account the guarantee LION has given to BAYER to refund to BAYER upon signature
of this amendment the amounts already paid by BAYER in regard certain hardware
upgrades and costs for purchasing Silicon Genetics' software GeNet (i.e. in
total 200.000 USD net), BAYER agrees and acknowledges herewith that all payments
in the past were done for services rendered and are non-

                                      -2-

<PAGE>

refundable.

4.       Entire Agreement

The Basic Agreement as amended by the First Amendment and this Second Amendment,
together with the Annexes to the Basic Agreement and to the First Amendment and
the Second Amendment and any other documents referenced herein or therein,
contains the entire agreement and understanding of the parties with respect to
the subject matter hereof, and shall supersede and merge all prior and
contemporaneous communications, agreements, arrangements, undertakings and
obligations with respect to the subject matter hereof. No addition to or
modification of any provision of this Agreement shall be binding upon the
parties unless made by a written instrument subsequent to the Effective Second
Amendment Date and signed by duly authorized representatives on behalf of each
of the parties. Any party contending that this Agreement has been amended or
modified shall be required to establish such amendment or modification by clear
and convincing evidence.

All provisions of the Basic Agreement as amended by the First Amendment and not
modified or amended by this Second Amendment shall remain in full force and
effect.

IN WITNESS WHEREOF, the parties have caused this Second Amendment to be executed
by their respective duly authorized representative as of the Effective Second
Amendment Date.

Wuppertal/Heidelberg: ______________________

BAYER AG

    /s/ J.A. Karlsson
By: ------------------------------------------
    Dr. J.A. Karlsson
    Ph-R Head

    /s/ van den Kerckhoff
By: ------------------------------------------
    Dr. van den Kerckhoff
    Patents & Licensing

LION bioscience AG

    /s/ Friedrich von Bohlen und Halbach
By: ---------------------------------------------
    Dr. Friedrich von Bohlen und Halbach, Chief Executive Officer

LION bioscience Research Inc.

    /s/ Anthony Caruso
By: ------------------------------------------
    Anthony Caruso, President

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]